Pfizer boosts rare disease pipeline with $5.4B acquisition of Global Blood Therapeutics
The $5.4 billion deal marks Pfizer's fourth acquisition in the last nine months
Pfizer is set to expand its rare disease treatment pipeline with the purchase of Global Blood Therapeutics, a biopharmaceutical company that develops treatments for blood disorders such as sickle cell disease.
Pfizer will acquire all Global Blood Therapeutics’ outstanding shares for $68.50 per share in cash, for a total enterprise value of approximately $5.4 billion, including debt and net cash acquired. According to a statement from Global Blood, both companies’ Boards of Directors have approved the transaction.
Global Blood Therapeutics makes Oxbryta, a prescription drug used to treat haemolytic anaemia (excess breakdown of red blood cells) in patients who have sickle cell disease. It was the first therapy approved in the European Union to target the underlying cause of sickle cell disease for patients 12 and older. Net sales for Oxbryta were approximately $195 million in 2021.
Sickle cell disease is a rare genetic disease where individuals produce an abnormal form of haemoglobin, which causes the red blood cells to become rigid, sticky and change from being disc-shaped to being crescent-shaped (like a sickle).
The acquisition comes as Pfizer seeks to reinvest its COVID-19 vaccine earnings through a number of strategic acquisitions. In May, Pfizer paid $11.6 billion to buy migraine drug maker Biohaven Pharmaceutical Holding and recently also completed a $6.7 billion deal to acquire Arena Pharmaceuticals.
‘Sickle cell disease is the most common inherited blood disorder, and it disproportionately affects people of African descent. We are excited to welcome GBT colleagues into Pfizer and to work together to transform the lives of patients, as we have long sought to address the needs of this underserved community,’ said Albert Bourla, Chairman and CEO of Pfizer.
‘The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle cell disease community and bring these treatments to patients as quickly as possible.’
Global Blood CEO Ted W. Love, M.D. added that the acquisition would ‘broaden and amplify our impact for patients and further propel much-needed innovation and resources for the care of people with sickle cell disease and other rare diseases, including populations in limited-resource countries.’
In addition to Oxbryta, Global Blood has multiple innovative drugs in its pipeline. The company is developing GBT021601 (GBT601), an oral sickle hemoglobin (HbS) polymerization inhibitor in the Phase 2 portion of a Phase 2/3 clinical study, as well as inclacumab, a fully human monoclonal antibody targeting P-selectin which is being evaluated in two Phase 3 clinical trials.
Shares of Global Blood rose 4.5% on Monday after the deal was announced.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance